You are here: Industry Insights > TYK2 inhibitor

News List

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China PharmaSources
May 16, 2025
InnoCare Pharma announced today that the first patient has been dosed in the Phase II/III clinical trial of its novel TYK2 inhibitor, Soficitinib (ICP-332), for the treatment patients with non-segmental vitiligo in China.
Data of InnoCare's ICP-488 for the Treatment of Psoriasis Presented at Late Breaking Oral Presentation of 2025 AAD PharmaSources
March 11, 2025
InnoCare Pharma; TYK2 inhibitor ICP - 488; psoriasis; 2025 AAD Annual Meeting; clinical data
InnoCare Announces First Subject Dosed in Clinical Trial of TYK2 Inhibitor ICP-332 in the U.S. July 24, 2024
Beijing, July 24, 2024 – InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases
InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA PharmaSources
June 11, 2024
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) ap
Latest data of InnoCare's ICP-332 for the Treatment of Atopic Dermatitis Presented at LBA Session of 2024 AAD Chunhua Lu
March 11, 2024
Efficacy and Safety of a Highly Selective Oral TYK2/JAK1 Inhibitor, ICP-332, in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase II, Randomized, Placebo-Controlled Trial.
InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-488 Meet Primary Endpoint in Psoriasis Patients PharmaSources
October 10, 2024
InnoCare Pharma announced today that phase II clinical study results of novel TYK2 (Tyrosine Kinase 2) inhibitor ICP-488 met the primary endpoint in adult patients with moderate-to-severe plaque psoriasis.
Ventyx Doses First Subject in VTX-958 Trial for Selective Allosteric TYK2 Inhibitor americanpharmaceuticalreview
March 23, 2021
Ventyx Biosciences announced the dosing of the first subject in a Phase 1 clinical trial of VTX-958, a novel and selective allosteric TYK2 inhibitor.